Alpha-1 Antitrypsin Antisense Oligonucleotide Modulates Protease-Antiprotease Imbalance without Further Aggravating Smoke-induced Lung Injury
R. Xiao, K. Stearns, T. Zelonina, M. P. Goldklang, K. Blomenkamp, J. Teckman, J. M. D'Armiento
Abstract
Alpha-1 antitrypsin (AAT) is a serum protease inhibitor that prevents lung injury from protease production during cigarette smoking but causes severe liver disease once mutated. A custom AAT antisense oligonucleotide (ASO) was found to be beneficial for the AATD liver disease by blocking the mutated AAT transcripts. Here we hypothesized that knock-down of AAT aggravates murine lung injury during smoke exposure and acute exacerbations of chronic obstructive pulmonary disease (COPD). C57BL/6J mice were randomly divided into 4 groups for each of the injury models, smoking (inhale for 3 months at 150mg/m3) and smoke-flu (inhale for 2 weeks and intranasal influenza virus). The ASO and control (No-ASO) were injected subcutaneously at 10ml/kg of body weight, starting with smoking or four days prior to influenza infection weekly at 50mg/kg. ASO treatment during a 3 month smoke exposure significantly increased the expression of Cela1 mRNA and decreased the serum and lung AAT expression. However, despite the decrease in AAT, neither the inflammatory cell counts in the bronchoalveolar lavage fluid (BALF) nor the lung structural changes were significantly affected by ASO treatment. We observed significant differences in inflammation and emphysema due to smoke exposure alone. With the smoke-flu model, similarly the major differences were found between smoke-flu and room air control, with no additional effect with ASO treatment. Off-target effects or compensatory mechanisms may account for this finding. Alternatively, the reduction of AAT with ASO treatment was not robust enough to lead to lung injury. The result also suggest that the AAT ASO approach for treating liver disease is relatively safe at the specified dose as it did not lead to detrimental outcomes in the lung. These potential mechanisms need to be further investigated in order to fully understand the impact of AAT inhibition on protease-antiprotease imbalance in the murine smoke exposure model.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cigarette smoke exposed airway epithelial cell-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency
N. Khodayari, R. Oshins, … M. Brantly·bioRxiv·Jul 7, 2022
- KF4 anti-CELA1 Antibody and Purified α1-Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine α1-Antitrypsin Deficiency
Andrew J. Devine, Noah J. Smith, … Brian M. Varisco·Chronic Obstructive Pulmonary Diseases Journal of the COPD FoundationPeer-reviewed·Nov 26, 2024
- A Compact Base Editor Rescues AATD-associated Liver and Lung Disease in Mouse Models
Jenny Gao, Nathan Bamidele, … Wen Xue·Molecular TherapyPeer-reviewed·Aug 28, 2025
- Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background
Regina A. Oshins, Alek M. Aranyos, … Nazli Khodayari·bioRxiv·Oct 11, 2024
- Role Of Chymotrypsin-Like Elastase 1 In Lung Physiology And in α1-Antitrypsin Deficiency
Rashika Joshi, Andrea Heinz, … Brian M. Varisco·bioRxiv·May 16, 2017
- AT2-intrinsic Z-AAT expression drives conserved inflammatory and proteotoxic stress responses and predisposes to emphysema
Carly Merritt, Rose Griffin, … Andrew A. Wilson·bioRxiv·Apr 9, 2026